Search clinical trials for: oral therapeutic

Total 29001 results

Roswell Park Cancer Institute
AVEO Pharmaceuticals, Inc.

Withdrawn

Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer

Stage III Renal Cell Cancer | Stage II Renal Cell Cancer
Sorrento Therapeutics, Inc.
Kimberly-Clark Corporation

Completed

Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002) (KCC-SMT-002)

Migraine Disorders

United States
AbbVie
KU Leuven; Syndesi Therapeutics

Completed

A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect

Cognitive Disorders

Belgium
Spero Therapeutics

Completed

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (ADAPT-PO)

Acute Pyelonephritis | Complicated Urinary Tract Infection

Bulgaria, Georgia, United States, Czechia, Estonia, Hungary, Latvia, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, Slovakia, South Africa, Ukraine
Akebia Therapeutics

Completed

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Anemia | Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Korea, Republic of, Portugal, Russian Federation, Ukraine, Poland, Argentina, Brazil, Germany, Mexico
Anavex Life Sciences Corp.
Anavex Australia Pty Ltd.; Anavex Germany GmbH; Anavex Canada Ltd.

Completed

ANAVEX2-73 for Treatment of Early Alzheimer's Disease

Alzheimer Disease

Australia, Canada, Germany, Netherlands, United Kingdom
Akebia Therapeutics

Completed

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

Anemia | End Stage Renal Disease

United States
Akebia Therapeutics

Completed

42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Anemia | Kidney Disease

United States
Calliditas Therapeutics AB
Eurofins Optimed; York Bioanalytical Solution

Completed

Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets

Phase 1

France
Calliditas Therapeutics AB

Completed

Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.

Primary Biliary Cirrhosis

United States, Israel, Belgium, Germany, United Kingdom, Spain, Greece, Canada, Italy
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Canada, Korea, Republic of, United Kingdom, Australia, Germany, Israel, France, Portugal, Bulgaria, Russian Federation, Ukraine, Poland, Brazil, Argentina, Mexico, Serbia
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Anemia | Non-Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Spain, Czechia, Korea, Republic of, Malaysia, Australia, New Zealand, United Kingdom, Germany, Turkey, Ukraine, France, Hungary, Austria, Israel, Bulgaria, Russian Federation, Romania, Slovakia, South Africa, Canad... and more
Akebia Therapeutics

Completed

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Anemia | Non-Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Korea, Republic of, Australia, New Zealand, South Africa, United Kingdom, Spain, Ukraine, Hungary, Israel, Bulgaria, Russian Federation, Mexico, Poland, Brazil, Argentina, Malaysia, Puerto Rico, France
Sun Yat-sen University

Active, not recruiting

HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC

Hepatocellular Carcinoma

China
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer

Stage I Oral Cavity Squamous Cell Carcinoma | Stage II Oral Cavity Squamous Cell Carcinoma

United States
United Therapeutics

Completed

An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Korea, Republic of, United States, Australia, Austria, Taiwan, China, Israel, Canada, India, Germany, Singapore, United Kingdom, Brazil, Italy, Netherlands, Argentina, Sweden, Chile, Denmark, France, Greece, Mexico, Poland
Laboratorios Andromaco S.A.

Completed

Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product

Therapeutic Equivalency

India
Allergan

Completed

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

Episodic Migraine

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Human Papillomavirus Infection | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage IVC Oropharyngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II Oropharyngeal... and other conditions

United States
Cerevel Therapeutics, LLC

Completed

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Schizophrenia

United States
Rhizen Pharmaceuticals SA
Incozen Therapeutics Pvt Ltd

Completed

Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.

SARS-CoV-2 Infection

India
Blade Therapeutics

Completed

Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers

Drug Drug Interaction

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (KARE)

Pruritus | Atopic Dermatitis

United States, Canada
Aimmune Therapeutics, Inc.

Completed

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) (PALISADE)

Peanut Allergy

United States, Spain, Ireland, Netherlands, Canada, United Kingdom, Germany, Denmark, Italy, Sweden
Aimmune Therapeutics, Inc.

Completed

PALISADE Follow-on Study (ARC004)

Peanut Allergy

United States, Spain, Netherlands, Italy, Canada, Germany, Ireland, Sweden, United Kingdom
Ziauddin University

Completed

Comparative Effect of Nigella Sativa and Conventional Management for OSMF

Oral Submucous Fibrosis

Pakistan
Aimmune Therapeutics, Inc.

Terminated

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Hen Egg Allergy

United States
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis (U-Accomplish)

Ulcerative Colitis (UC)

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Orphelia Pharma

Completed

Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules

Therapeutic Equivalency

France
Marijn Lijffijt, PhD
Michael E. DeBakey VA Medical Center; VistaGen Therapeutics, Inc.

Completed

Electrophysiological Biomarkers of AV-101

Healthy

United States
Immunoflex Therapeutics Inc.
University of British Columbia; Dicentra Inc.

Completed

Immune Diversity Response to Oral Dosing of Nutritional Health Products in Healthy Participants

Immunity Disorders

Canada
Fulcrum Therapeutics

Completed

Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) (FSHD)

Facioscapulohumeral Muscular Dystrophy (FSHD)

United States, Canada, France, Spain
Corcept Therapeutics

Completed

A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers

Healthy

India
Antios Therapeutics, Inc

Completed

A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects

Drug Interaction

Canada
Sage Therapeutics

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B

Huntington Disease

United States
Indonesia University

Completed

A New Intervention Method to Enhance Oral Feeding Ability in Premature Infants: A Randomized Controlled Trial

Premature | Feeding; Difficult, Newborn

Indonesia
Cerevel Therapeutics, LLC

Completed

Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants

Healthy

United States
Brigham and Women's Hospital
United Therapeutics

Completed

Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon

Raynaud's Phenomenon

United States
Cyclacel Pharmaceuticals, Inc.

Terminated

A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors

Solid Tumors

United States
The Lymphoma Academic Research Organisation
Karyopharm Therapeutics Inc

Completed

A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP (SELINDA)

B-cell Lymphoma

Belgium, France
TG Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) (ULTIMATE 1)

Relapsing Multiple Sclerosis (RMS)

United States
TG Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) (ULTIMATE II)

Relapsing Multiple Sclerosis (RMS)

United States
Aimmune Therapeutics, Inc.

Completed

Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT (ARC001)

Peanut Allergy

United States
Fulcrum Therapeutics

Completed

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

Healthy Adult Subjects

United States
Alaunos Therapeutics

Terminated

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

Diffuse Intrinsic Pontine Glioma | Pediatric Brain Tumor

United States
Blade Therapeutics

Completed

Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations

Relative Bioavailability

Australia
Aimmune Therapeutics, Inc.

Completed

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

Peanut Allergy

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy

HIV Infections

United States, Puerto Rico

Search clinical trials for: oral therapeutic

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations